Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Blueprint Medicines to acquire LNG-451 with Lengo Therapeutics acquisition

Nov. 30, 2021

Discovery of the novel BCL6 BTB-specific inhibitor, AP-4-287

Nov. 29, 2021

Merck & Co. synthesizes new LAAO inhibitors

Nov. 29, 2021

Study reports tumors change as patients age

Nov. 26, 2021

Merck, Cancer Research Technology divulge YAP1/TEAD interaction inhibitors

Nov. 26, 2021

New MAP4K1 inhibitors synthesized at Pfizer

Nov. 26, 2021

Adenosine A2A receptor antagonists identified at Adorx Therapeutics

Nov. 26, 2021

Restoration of NXTAR as a novel approach for prostate cancer treatment with enzalutamide

Nov. 25, 2021

Meiji Seika Pharma divulges histamine H4 receptor antagonists

Nov. 25, 2021

New PADI4 inhibitors synthesized at Gilead

Nov. 25, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...